Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®
- Details
- Category: Bayer
Bayer confirmed that Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit in U.S. Federal Court in the Southern District of New York (New York) against Watson Pharmaceuticals, Inc., Watson Laboratories, Inc. and Sandoz, Inc.
FTY720, a novel oral therapy in development for multiple sclerosis
- Details
- Category: Novartis
The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new clinical data presented from an ongoing Phase II study extension[1].
GlaxoSmithKline and Regulus Therapeutics form strategic alliance
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Regulus Therapeutics LLC (Regulus) announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
Bayer donates €250,000 for patients with hemophilia
- Details
- Category: Bayer
In celebration of World Hemophilia Day on April 17th, Bayer HealthCare donates €250,000 to the World Federation of Hemophilia (WFH) and more than 950,000 international units of Kogenate® FS (Antihemophilic Factor [Recombinant]).
Grindeks JSC is opening new representative office in Uzbekistan
- Details
- Category: Business
Grindeks JSC is expanding its activities in the former soviet republics members of Commonwealth of Independent States by opening new representative office in Uzbekistan. The new representative office will have been cooperating with medicines administrating state authorities, Uzbekistan's companies engaged in pharmaceutical and medicinal products wholesale and retail business, as well as providing drug registration processes and medicaments marketing.
Pfizer Reports First-Quarter 2008 Results
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) reported results for the first-quarter 2008. The Company recorded revenues of $11.8 billion, a decrease of 5% compared with $12.5 billion in the year-ago quarter, primarily due to the March 2007 loss of U.S. exclusivity of Norvasc as well as the January 2008 loss of U.S. exclusivity of Zyrtec, which Pfizer ceased selling in late January 2008. In the first-quarter 2008, Norvasc and Zyrtec revenues decreased by $556 million and $344 million, respectively, compared with the prior-year quarter.
Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced financial results for the first quarter ended March 31, 2008.
- Diluted earnings per share, excluding specified items, were $0.63, reflecting 14.5 percent growth, at the upper end of Abbott's previously announced guidance range of $0.61 to $0.63. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.60, up 33.3 percent.
More Pharma News ...
- Roche fully acquires privately-owned biotech company Piramed
- Patients with early Parkinson's disease show better symptom control
- AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
- Dr. Reddy's acquires Jet Generici Srl. Acquisition to establish Generics business in Italy
- Novartis to first acquire 25% stake from Nestlé for USD 143.18 per share for USD 11 billion
- The first vaccine licensed to complete the rotavirus immunisation series by four months of age
- International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM)